2022
19th SEPTEMBER
ESCRSToday
ESCRS Today is a daily newspaper packed with highlights of the day’s main events and industry symposia.
iNOVATION
Survey shows concerns among clinicians and industry Clinical ophthalmologists have a lot on their minds, and so do expressed ongoing concern about increased regulation, the industry leaders that provide the tools they use, a new survey larger companies were somewhat more concerned about suggests. The findings come from a survey of 203 pre-registered supply chain issues, whereas smaller companies were more attendees of the ESCRS iNovation Day meeting this past Friday. concerned about finding and keeping employees than their Ophthalmologists and industry representatives both cited larger counterparts. increased regulation and decreasing reimbursement as major concerns. In what two clinical areas would you invest the greatest amount Non-doctors showed an elevated of resources toward future innovation at the moment? concern for supply chain issues, while doctors showed slightly more concern about more economic issues—recession and inflation. Interestingly, neither doctors nor non-doctors appeared to have major concerns about COVID restrictions or resurgence. The survey highlighted some surprising contrasts among the concerns of small companies versus larger companies. While both groups Doctors Non-doctors
WELCOME
VISIT OUR BOOTH
TO LEARN MORE ABOUT iLINK™ V
INTERVENE EARLY WITH THE iLINK V CORNEAL CROSS-LINKING PLATFORM
Slow or halt progressive keratoconus and help preserve your patients’ vision.
The iLink™ V corneal cross-linking platform comprises of proprietary VibeX® Rapid riboflavin and the ultra-violet A (UVA) light from the KXL® System used for the treatment of keratoconus.
INDICATIONS: The KXL™ system delivers a uniform, metered dose of UVA light to a targeted treatment area for the intended use of illuminating the cornea during corneal crosslinking procedures stabilising cornea which have been weakened by disease or by refractive surgery. VibeX Rapid™ (riboflavin) are indicated for use in the treatment of corneal strengthening, progressive keratoconus, iatrogenic ectasia, pellucid marginal degeneration. VibeX Rapid™ riboflavin formulation is CE Marked. Glaukos Corporation • 229 Avenida Fabricante • San Clemente, CA • 92672 • USA EMAIL: info@glaukos.com WEBSITE: www.glaukos.com © 2022 Glaukos. iLink™ is a trademark of Glaukos Corp. KXL™ and Vibex Rapid™ are trademarks of Avedro, Inc. a Glaukos Company. PM-EU-0117: MA-02142A